(Q34481552)

2 August 2017

1 reference

title

Development of agents for the treatment of systemic sclerosis (English)

1 reference

2 August 2017

Herrick AL

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

7

1 reference

2 August 2017

page(s)

1255-1264

1 reference

Macrovascular disease and systemic sclerosis

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Advances in treatment of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Biological agents: a novel approach to the therapy of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Hematopoietic stem cell transplantation in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.7.1255

10.1517/13543784.10.7.1255

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference